Viking Therapeutics, Inc.
General ticker "VKTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.6B (TTM average)
Viking Therapeutics, Inc. follows the US Stock Market performance with the rate: 31.6%.
Estimated limits based on current volatility of 3.9%: low 34.65$, high 37.47$
Factors to consider:
- Total employees count: 36 (+33.3%) as of 2024
- Top business risk factors: Market competition, Market risk, Manufacturing risks, Labor/talent shortage/retention, Product liability
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.05$, 47.23$]
- 2025-12-31 to 2026-12-31 estimated range: [12.79$, 33.77$]
Financial Metrics affecting the VKTX estimates:
- Negative: with PPE of -41.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.96 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: -14.38 < Investing cash flow per share per price, % of -12.33
- Positive: Shareholder equity ratio, % of 96.91 > 63.39
- Negative: negative Industry operating income (median)
- Negative: -0.75 < Inventory ratio change, % of 0
Short-term VKTX quotes
Long-term VKTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $70.36MM | $100.83MM | $150.92MM |
| Operating Income | $-70.36MM | $-100.83MM | $-150.92MM |
| Non-Operating Income | $2.72MM | $14.93MM | $40.96MM |
| Interest Expense | $0.00MM | $0.09MM | $0.09MM |
| R&D Expense | $54.23MM | $63.81MM | $101.64MM |
| Income(Loss) | $-67.64MM | $-85.89MM | $-109.96MM |
| Profit(Loss)* | $-68.87MM | $-85.89MM | $-109.96MM |
| Stockholders Equity | $145.32MM | $348.42MM | $880.28MM |
| Assets | $168.53MM | $368.49MM | $908.32MM |
| Operating Cash Flow | $-48.40MM | $-73.38MM | $-87.79MM |
| Investing Cash Flow | $54.75MM | $-179.09MM | $-553.37MM |
| Financing Cash Flow | $4.16MM | $271.38MM | $612.46MM |
| Earnings Per Share** | $-0.90 | $-0.91 | $-1.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.